CBIO (Crescent Biopharma) Inventories, Work In Process: $0.00 Mil (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Inventories, Work In Process?

Crescent Biopharma CBIO +9.24% 10 Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Crescent Biopharma's work in process for the quarter that ended in Mar. 2026 was $0.00 Mil.

Crescent Biopharma Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Inventories, Work In Process Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Inventories, Work In Process
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
CBIO
10GF Score
Crescent Biopharma Inc CBIO
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.00 Mil mean?
Crescent Biopharma (CBIO) has a Inventories, Work In Process of $0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Inventories, Work In Process too high?
Crescent Biopharma's current Inventories, Work In Process is $0.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Inventories, Work In Process compare to RIGL and GYRE?
Crescent Biopharma's Inventories, Work In Process of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Inventories, Work In Process is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Inventories, Work In Process of $0.00 Mil. The current Inventories, Work In Process is $0.00 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price